ATE343387T1 - S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen. - Google Patents

S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.

Info

Publication number
ATE343387T1
ATE343387T1 AT01932011T AT01932011T ATE343387T1 AT E343387 T1 ATE343387 T1 AT E343387T1 AT 01932011 T AT01932011 T AT 01932011T AT 01932011 T AT01932011 T AT 01932011T AT E343387 T1 ATE343387 T1 AT E343387T1
Authority
AT
Austria
Prior art keywords
ziprasidone
dihydro
methyl
treatment
eye diseases
Prior art date
Application number
AT01932011T
Other languages
English (en)
Inventor
Chandra Prakash
Teresa Smolarek
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE343387(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE343387T1 publication Critical patent/ATE343387T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT01932011T 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen. ATE343387T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16

Publications (1)

Publication Number Publication Date
ATE343387T1 true ATE343387T1 (de) 2006-11-15

Family

ID=26903852

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01932011T ATE343387T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
AT04013380T ATE345818T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
AT06116051T ATE391507T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04013380T ATE345818T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
AT06116051T ATE391507T1 (de) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie

Country Status (44)

Country Link
US (1) US20060287336A1 (de)
EP (3) EP1286672B1 (de)
JP (2) JP2003534381A (de)
KR (1) KR20030007824A (de)
CN (1) CN1431901A (de)
AP (2) AP1747A (de)
AR (1) AR028937A1 (de)
AT (3) ATE343387T1 (de)
AU (1) AU2001258690A1 (de)
BG (1) BG107267A (de)
BR (1) BR0111271A (de)
CA (1) CA2410618A1 (de)
CY (1) CY1105992T1 (de)
CZ (1) CZ20023860A3 (de)
DE (3) DE60133596D1 (de)
DK (1) DK1468686T3 (de)
DO (1) DOP2001000181A (de)
EA (1) EA007068B1 (de)
EC (1) ECSP024369A (de)
EE (1) EE200200670A (de)
ES (1) ES2277170T3 (de)
GE (1) GEP20053512B (de)
HN (1) HN2001000119A (de)
HR (1) HRP20020953A2 (de)
HU (1) HUP0301747A2 (de)
IL (2) IL152782A0 (de)
IS (1) IS6619A (de)
MA (1) MA26908A1 (de)
MX (1) MXPA02011862A (de)
NO (1) NO325077B1 (de)
NZ (1) NZ551012A (de)
OA (1) OA12267A (de)
PA (1) PA8518301A1 (de)
PE (1) PE20011329A1 (de)
PL (1) PL365576A1 (de)
PT (2) PT1698338E (de)
SI (1) SI1468686T1 (de)
SK (1) SK16622002A3 (de)
SV (1) SV2002000473A (de)
UA (1) UA79425C2 (de)
UY (1) UY26742A1 (de)
WO (1) WO2001091756A2 (de)
YU (1) YU90702A (de)
ZA (1) ZA200209665B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419493B2 (en) 2002-12-13 2008-09-02 Regents Of The University Of Minnesota Scleral depressor
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA47467C2 (uk) * 1996-05-07 2002-07-15 Файзер Інк. Тригідрат мезилату 5-(2-(4-(1,2-бензизотіазол-3-іл)-1-піперазиніл)етил)-6-хлор-1,3-дигідро-2(1н)-індол-2-ону (зипразидону), фармацевтична композиція та спосіб лікування психічних розладів
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EP0985414B1 (de) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
CA2363942A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
ECSP024369A (es) 2003-02-06
EP1468686B1 (de) 2006-11-22
ATE391507T1 (de) 2008-04-15
AP2005003272A0 (en) 2005-03-31
KR20030007824A (ko) 2003-01-23
NO20025760L (no) 2003-01-15
DE60124093D1 (de) 2006-12-07
US20060287336A1 (en) 2006-12-21
WO2001091756A2 (en) 2001-12-06
NO325077B1 (no) 2008-01-28
CY1105992T1 (el) 2011-04-06
EP1698338B1 (de) 2008-04-09
SV2002000473A (es) 2002-10-24
EP1698338A3 (de) 2006-09-20
YU90702A (sh) 2005-11-28
CA2410618A1 (en) 2001-12-06
ZA200209665B (en) 2003-11-28
WO2001091756A3 (en) 2002-09-26
BG107267A (bg) 2003-06-30
CZ20023860A3 (cs) 2004-01-14
PE20011329A1 (es) 2002-01-15
DE60133596D1 (de) 2008-05-21
DE60124791T2 (de) 2007-09-13
PL365576A1 (en) 2005-01-10
NZ551012A (en) 2008-04-30
JP2003534381A (ja) 2003-11-18
EP1468686A2 (de) 2004-10-20
GEP20053512B (en) 2005-05-10
EP1468686A3 (de) 2004-12-01
OA12267A (en) 2004-01-20
SI1468686T1 (sl) 2007-04-30
IL152782A (en) 2007-10-31
EA007068B1 (ru) 2006-06-30
PA8518301A1 (es) 2002-09-17
UA79425C2 (en) 2007-06-25
JP2008056700A (ja) 2008-03-13
AU2001258690A1 (en) 2001-12-11
HRP20020953A2 (en) 2005-02-28
MXPA02011862A (es) 2003-04-10
DE60124791D1 (de) 2007-01-04
NO20025760D0 (no) 2002-11-29
EP1698338A2 (de) 2006-09-06
MA26908A1 (fr) 2004-12-20
SK16622002A3 (sk) 2004-07-07
ATE345818T1 (de) 2006-12-15
EP1286672B1 (de) 2006-10-25
HN2001000119A (es) 2001-09-11
HUP0301747A2 (hu) 2003-09-29
AP1747A (en) 2007-05-31
PT1698338E (pt) 2008-06-03
BR0111271A (pt) 2003-06-10
IS6619A (is) 2002-11-14
IL152782A0 (en) 2003-06-24
AR028937A1 (es) 2003-05-28
EE200200670A (et) 2004-08-16
EA200201168A1 (ru) 2003-06-26
CN1431901A (zh) 2003-07-23
PT1468686E (pt) 2007-01-31
UY26742A1 (es) 2001-12-28
EP1286672A2 (de) 2003-03-05
AP1831A (en) 2008-02-26
DK1468686T3 (da) 2007-03-12
ES2277170T3 (es) 2007-07-01
DOP2001000181A (es) 2002-04-15

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
DE69903543T2 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties